Research Analysts Offer Predictions for GSK plc’s FY2024 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Investment analysts at Zacks Research decreased their FY2024 earnings per share estimates for shares of GSK in a report released on Tuesday, October 1st. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings of $4.11 per share for the year, down from their previous estimate of $4.26. The consensus estimate for GSK’s current full-year earnings is $4.17 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $1.01 EPS, FY2025 earnings at $4.51 EPS and FY2026 earnings at $5.00 EPS.

Other equities analysts have also recently issued research reports about the company. Citigroup raised GSK to a “strong-buy” rating in a research report on Monday, June 24th. Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Finally, Jefferies Financial Group boosted their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $50.00.

GSK Price Performance

NYSE GSK opened at $38.82 on Friday. GSK has a twelve month low of $33.67 and a twelve month high of $45.92. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The stock has a market capitalization of $80.45 billion, a PE ratio of 14.07, a P/E/G ratio of 1.31 and a beta of 0.65. The stock has a 50-day simple moving average of $41.57 and a 200 day simple moving average of $41.50.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The business had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a $0.3843 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a dividend yield of 3.96%. The ex-dividend date is Friday, August 16th. GSK’s dividend payout ratio is currently 54.71%.

Insider Activity

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On GSK

Large investors have recently modified their holdings of the stock. Farmers Trust Co. bought a new stake in GSK during the 3rd quarter worth approximately $203,000. SG Americas Securities LLC grew its position in GSK by 167.3% during the 3rd quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock worth $767,000 after acquiring an additional 11,749 shares during the last quarter. Trust Co. of Toledo NA OH grew its position in GSK by 6.6% during the 3rd quarter. Trust Co. of Toledo NA OH now owns 32,679 shares of the pharmaceutical company’s stock worth $1,336,000 after acquiring an additional 2,015 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in GSK during the 2nd quarter worth approximately $52,487,000. Finally, Clifford Capital Partners LLC grew its position in GSK by 21.3% during the 2nd quarter. Clifford Capital Partners LLC now owns 358,291 shares of the pharmaceutical company’s stock worth $13,794,000 after acquiring an additional 63,033 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.